Jean‐Paul Nicolas

2.2k total citations
30 papers, 1.8k citations indexed

About

Jean‐Paul Nicolas is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Endocrine and Autonomic Systems. According to data from OpenAlex, Jean‐Paul Nicolas has authored 30 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 18 papers in Cellular and Molecular Neuroscience and 6 papers in Endocrine and Autonomic Systems. Recurrent topics in Jean‐Paul Nicolas's work include Receptor Mechanisms and Signaling (18 papers), Neuroscience and Neuropharmacology Research (9 papers) and Neuropeptides and Animal Physiology (7 papers). Jean‐Paul Nicolas is often cited by papers focused on Receptor Mechanisms and Signaling (18 papers), Neuroscience and Neuropharmacology Research (9 papers) and Neuropeptides and Animal Physiology (7 papers). Jean‐Paul Nicolas collaborates with scholars based in France, Netherlands and Germany. Jean‐Paul Nicolas's co-authors include Adrian Newman‐Tancredi, Jean A. Boutin, Alain P. Gobert, Jean‐Michel Rivet, Mark J. Millan, F. Lejeune, Didier Cussac, Valérie Audinot, Philippe Delagrange and Emmanuel Canet and has published in prestigious journals such as Journal of Biological Chemistry, Angewandte Chemie International Edition and Cancer Research.

In The Last Decade

Jean‐Paul Nicolas

30 papers receiving 1.8k citations

Peers

Countries citing papers authored by Jean‐Paul Nicolas

Since Specialization

Citations

This map shows the geographic impact of Jean‐Paul Nicolas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Paul Nicolas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Paul Nicolas more than expected).

Fields of papers citing papers by Jean‐Paul Nicolas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Paul Nicolas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Paul Nicolas. The network helps show where Jean‐Paul Nicolas may publish in the future.

Co-authorship network of co-authors of Jean‐Paul Nicolas

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Paul Nicolas. A scholar is included among the top collaborators of Jean‐Paul Nicolas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Paul Nicolas. Jean‐Paul Nicolas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Production of the Bengamide Class of Marine Natural Products in Myxobacteria: Biosynthesis and Structure–Activity Relationships 2015 ·Angewandte Chemie International Edition ·Silke C. Wenzel, Holger Hoffmann, Jidong Zhang, Laurent Debüssche, (unknown), Michael Kurz, (unknown), Peer Lukat, (unknown), (unknown), Dietmar Schummer, Jean‐Paul Nicolas, Loreley Calvet, (unknown), Patricia Vrignaud, Agnes Mühlenweg, Stefan Pelzer, Rolf Müller, Mark Brönstrup	35
2	The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in MET -Amplified Cancer 2014 ·Molecular Cancer Therapeutics ·Coumaran Égile, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jean‐Paul Nicolas, (unknown), (unknown), Elisa Francesconi, (unknown), Anne‐Marie Lefebvre, Conception Nemecek, Loreley Calvet, Hélène Goulaouic	23
3	Abstract 845: In vitro and in vivo pharmacology of SAR125844, a potent and selective intravenous MET kinase inhibitor undergoing Phase I clinical trial 2012 ·Cancer Research ·Hélène Goulaouic, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jean‐Paul Nicolas, Loreley Calvet, Coumaran Égile, Conception Nemecek, Christoph Lengauer	1
4	Functional characterization of human neuropeptide Y receptor subtype five specific antagonists using a luciferase reporter gene assay 2004 ·Cellular Signalling ·Philippe Beauverger, Marianne Rodriguez, Jean‐Paul Nicolas, Valérie Audinot, (unknown), Sandra Dromaint, Nadine Nagel, (unknown), (unknown), Jean‐Pierre Galizzi, Daniel‐Henri Caignard, Ignacio Aldana, Antonio Monge, Pascale Chomarat, Jean A. Boutin	2
5	Melanin-concentrating hormone and its receptors: state of the art 2002 ·Canadian Journal of Physiology and Pharmacology ·Jean A. Boutin, Thomas Suply, Valérie Audinot, Marianne Rodriguez, Philippe Beauverger, Jean‐Paul Nicolas, Jean‐Pierre Galizzi, Jean‐Luc Fauchère	42
6	Ligand modulation of [35S]GTPγS binding at human α2A, α2B and α2C adrenoceptors 2002 ·Cellular Signalling ·Valérie Audinot, (unknown), Jean‐Paul Nicolas, Philippe Beauverger, Adrian Newman‐Tancredi, Mark J. Millan, (unknown), Frédéric Bornancin, Emmanuel Canet, Jean A. Boutin	25
7	Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and α1/α2-Adrenoceptor 2002 ·Journal of Pharmacology and Experimental Therapeutics ·Adrian Newman‐Tancredi, Didier Cussac, Valérie Audinot, Jean‐Paul Nicolas, Frédéric De Ceuninck, Jean A. Boutin, Mark J. Millan	151
8	Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of α₂‐adrenergic and serotonin_2C receptors: a comparison with citalopram 2000 ·European Journal of Neuroscience ·Mark J. Millan, Alain P. Gobert, Jean‐Michel Rivet, (unknown), Didier Cussac, Adrian Newman‐Tancredi, Anne Dekeyne, Jean‐Paul Nicolas, F. Lejeune	139
9	Agonist and antagonist actions of yohimbine as compared to fluparoxan at ?2-adrenergic receptors (AR)s, serotonin (5-HT)1A, 5-HT1B, 5-HT1D and dopamine D2 and D3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states 2000 ·Synapse ·Mark J. Millan, Adrian Newman‐Tancredi, (unknown), Didier Cussac, F. Lejeune, Jean‐Paul Nicolas, (unknown), Jean‐Pierre Galizzi, Jean A. Boutin, Jean‐Michel Rivet, Anne Dekeyne, Alain P. Gobert	168
10	Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat 2000 ·Synapse ·Alain P. Gobert, Jean‐Michel Rivet, F. Lejeune, Adrian Newman‐Tancredi, (unknown), Jean‐Paul Nicolas, Laetitia Cistarelli, Christophe Melon, Mark J. Millan	271
11	Screening of Ligand Binding on Melatonin Receptor Using Non-Peptide Combinatorial Libraries 2000 ·Journal of Receptors and Signal Transduction ·Jean A. Boutin, (unknown), (unknown), Jean‐Paul Nicolas, Jean‐Luc Fauchère, Michel Langlois, (unknown), Philippe Delagrange, Emmanuel Canet	5
12	Synthesis of a small library of phenylalkylamide derivatives as melatoninergic ligands for human mt1 and MT2 receptors 2000 ·Bioorganic & Medicinal Chemistry ·(unknown), (unknown), Jean‐Paul Nicolas, Jean A. Boutin, Philippe Delagrange, Pierre Renard, Michel Langlois	14
13	Synthesis of Phenalene and Acenaphthene Derivatives as New Conformationally Restricted Ligands for Melatonin Receptors 2000 ·Journal of Medicinal Chemistry ·(unknown), Monique Mathé‐Allainmat, Jean Andrieux, (unknown), Jean A. Boutin, Jean‐Paul Nicolas, Caroline Bennejean, Philippe Delagrange, Michel Langlois	31
14	NPY receptor subtype in the rabbit isolated ileum 1999 ·British Journal of Pharmacology ·Michel Félétou, Jean‐Paul Nicolas, Marianne Rodriguez, Philippe Beauverger, Jean‐Pierre Galizzi, Jean A. Boutin, J Duhault	22
15	NPY receptor subtypes involved in the contraction of the proximal colon of the rat 1998 ·Regulatory Peptides ·Michel Félétou, Marianne Rodriguez, Philippe Beauverger, Martine Germain, (unknown), Sandra Dromaint, (unknown), (unknown), Jean‐Michel Henlin, Jean‐Paul Nicolas, Jean A. Boutin, Jean‐Pierre Galizzi, Jean‐Luc Fauchère, Emmanuel Canet, J Duhault	30
16	Actions of α2 adrenoceptor ligands at α2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for α2A adrenoceptors 1998 ·Naunyn-Schmiedeberg s Archives of Pharmacology ·Adrian Newman‐Tancredi, Jean‐Paul Nicolas, Valérie Audinot, (unknown), Laurence Verrièle, Manuelle Touzard, C. Chaput, (unknown), Mark J. Millan	110
17	S 18126 ({2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl}), a Potent, Selective and Competitive Antagonist at Dopamine D4 Receptors: An In Vitro and In Vivo Comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and Raclopride 1998 ·Journal of Pharmacology and Experimental Therapeutics ·Mark J. Millan, Adrian Newman‐Tancredi, Mauricette Brocco, Alain P. Gobert, Franćoise Lejeune, Valérie Audinot, Jean‐Michel Rivet, Rudy Schreiber, Anne Dekeyne, Michael Spedding, Jean‐Paul Nicolas, Jean-Louis Péglion	68
18	Identification of the Binding Domain for Secretory Phospholipases A2 on Their M-type 180-kDa Membrane Receptor 1995 ·Journal of Biological Chemistry ·Jean‐Paul Nicolas, Gérard Lambeau, Michel Lazdunski	67
19	Structural Elements of Secretory Phospholipases A2 Involved in the Binding to M-type Receptors 1995 ·Journal of Biological Chemistry ·Gérard Lambeau, Philippe Ancian, Jean‐Paul Nicolas, Sigrid H.W. Beiboer, Danielle Moinier, Hubertus M. Verheij, Michel Lazdunski	102
20	Bioclimatologie Humaine de Saint-Louis du Senegal (Essai de methodologie bioclimatologique) 1961 ·Geographical Review ·R. G. Stone, Jean‐Paul Nicolas	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact